HUTCHMED (China) Limited (LON:HCM - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 269.41 ($3.35) and traded as low as GBX 210.45 ($2.62). HUTCHMED shares last traded at GBX 211 ($2.63), with a volume of 76,816 shares trading hands.
HUTCHMED Stock Performance
The company has a current ratio of 2.81, a quick ratio of 2.97 and a debt-to-equity ratio of 11.78. The company has a market cap of £1.86 billion, a price-to-earnings ratio of -5,450.00 and a beta of 0.76. The stock has a 50 day moving average price of GBX 239.21 and a two-hundred day moving average price of GBX 268.17.
About HUTCHMED
(
Get Free Report)
We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.
We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.
HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
